Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on the Effectiveness of PQ Grass for Children and Teens with Seasonal Allergies from Grass Pollen

Fast replyRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a treatment called PQ Grass in children and adolescents who suffer from seasonal allergic rhinitis or rhinoconjunctivitis caused by exposure to grass pollen. These conditions are commonly known as hay fever, which can cause symptoms like sneezing, runny nose, and itchy eyes during certain seasons when grass pollen is in the air. The treatment being tested, PQ Grass, is given as an injection under the skin and is designed to help reduce these allergic reactions over time.

The purpose of the study is to evaluate how effective and safe PQ Grass is for children and teenagers with these allergies. Participants in the study will receive either the PQ Grass treatment or a placebo, which looks like the treatment but does not contain the active ingredient. The study will be conducted over several years to see if the benefits of the treatment last even after stopping the injections. During the study, participants will have regular check-ups to monitor their health and any changes in their allergy symptoms.

Throughout the trial, participants will be asked to visit the study site for assessments and to receive their injections. The study aims to provide valuable information on whether PQ Grass can offer long-term relief from grass pollen allergies in young people. This research could potentially lead to better treatment options for those affected by seasonal allergies.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the participant will be required to provide written informed consent from a legal representative. This is necessary to ensure understanding and agreement to participate in the trial.

  2. Step 2

    Initial assessment

    An initial assessment will be conducted to confirm eligibility. This includes a medical evaluation, spirometry or peak flow measurements, and a skin prick test to confirm sensitivity to grass pollen.

  3. Step 3

    Treatment phase part A

    During Part A of the treatment phase, the participant will receive the investigational product, PQ Grass 27600 SU, or a placebo. The treatment is administered as a subcutaneous injection.

    The participant will be monitored for efficacy and safety, with regular visits to assess symptoms and any side effects.

  4. Step 4

    Treatment phase part B

    In Part B, the long-term efficacy of the treatment will be evaluated. This phase involves continued monitoring of symptoms and any side effects over a period of treatment-free follow-up.

    The participant will not receive any active treatment during this phase, allowing for observation of sustained effects.

  5. Step 5

    Follow-up assessments

    Throughout the trial, follow-up assessments will be conducted to evaluate the participant's response to the treatment. This includes measuring the quality of life and any changes in clinical laboratory values.

    Regular visits will be scheduled to ensure the participant's health and safety are maintained.

  6. Step 6

    Completion of the trial

    Upon completion of the trial, a final assessment will be conducted to gather comprehensive data on the participant's experience and the treatment's efficacy.

    The trial is estimated to end by October 31, 2032.

Who can join the trial?

11 criteria

  • Written informed consent must be provided by a legal representative on behalf of the child.
  • The child should be between 4 to 16 years old when the consent form is signed and between 5 to 16 years old at the first visit.
  • Both boys and girls can participate.
  • Girls who can have children must have a negative pregnancy test at all visits and agree to use birth control if they are sexually active.
  • The child should be in good general health, as determined by a doctor after a medical check-up.
  • The child must have a history of moderate to severe seasonal allergies caused by grass pollen for at least one year or since their 5th birthday, even after using allergy medicine.
  • The child must have a positive skin test for grass pollen, which means a reaction of at least 3 mm in size, and no reaction to a negative control test.
  • The child must have a specific type of allergy antibody to grass pollen, shown by a test result of class 2 or higher.
  • The child must be able to perform breathing tests like spirometry or peak flow measurements.
  • The child must have a breathing test result showing a forced expiratory volume (FEV1) of at least 80% of what is expected, or a ratio of FEV1 to forced vital capacity (FVC) of at least 75%, or a peak expiratory flow rate (PEFR) of at least 75% of what is expected.
  • The child must be able to follow the schedule for taking the study medication and attending visits.

Who cannot join the trial?

7 criteria

  • Children who are not between the ages of 2 and 18 cannot participate.
  • Children who do not have **seasonal allergic rhinitis** (a type of allergy that causes sneezing, runny nose, and itchy eyes) caused by grass pollen cannot participate.
  • Children who have other health conditions that might interfere with the study cannot participate.
  • Children who are taking certain medications that might affect the study results cannot participate.
  • Children who have had a severe allergic reaction to similar treatments in the past cannot participate.
  • Children who are part of another clinical trial cannot participate.
  • Children who are unable to follow the study procedures cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

PQ Grass 27600 SU is a medication being studied for its effectiveness and safety in treating children and adolescents who suffer from seasonal allergic rhinitis or rhinoconjunctivitis caused by grass pollen. The trial aims to determine how well this medication works in reducing allergy symptoms and whether its benefits last over a long period.

What is already known about the treatment

PQ Grass 27600 SU – This medication is administered orally and is designed to treat seasonal allergic rhinitis and rhinoconjunctivitis caused by grass pollen exposure. It is currently being studied in clinical trials to assess its effectiveness and safety in children and adolescents. The main therapeutic indication is to alleviate symptoms associated with grass pollen allergies. At the molecular level, it works by modulating the immune response to reduce allergic reactions. It is classified pharmacologically as an allergen immunotherapy.

Investigated diseases

Seasonal Allergic Rhinitis – This condition is an allergic reaction that occurs at certain times of the year, typically when pollen levels are high. It is characterized by symptoms such as sneezing, runny or stuffy nose, and itchy eyes. The condition is triggered by exposure to allergens like grass pollen. As the season progresses, symptoms may vary in intensity, often worsening during peak pollen times. The body's immune system overreacts to the pollen, causing inflammation in the nasal passages. Over time, individuals may notice patterns in their symptoms corresponding to specific seasons.
Trial detailsLast updated 7 Oct 2026
Age0-17PhasePhase IIITrial ID2023-508520-36-00Protocol codePQGrass308Estimated enrolment408 patientsSponsorAllergy Therapeutics (UK) Limited

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.